Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 347
Appendix D Meeting Agendas Thursday, February 3, 2011 Keck Center of the National Academies 500 Fifth Street, NW Washington, DC 20001 1:00–1:15 pm Committee Introductions and Chair’s Opening Statement Jane Henney Committee Chair 1:10–1:30 pm Charge to the Committee Lawrence Deyton, M.D., M.S.P.H. Director Center for Tobacco Products U.S. Food and Drug Administration (FDA) 1:30–2:00 pm Discussion About the Charge Committee and FDA Representatives 2:00–3:00 pm Public Comment 3:00 pm Adjourn 347
OCR for page 348
348 STUDIES ON MODIFIED RISK TOBACCO PRODUCTS Monday, May 9, 2011 Embassy Suites 900 Tenth Street, NW Washington, DC 20001 9:45–10:00 am Welcome and Introductions Jane Henney Committee Chair 10:00–11:30 am Panel Discussion I: Tobacco Manufacturers Moderator: Peter Honig 10:00–11:00 am: Presentations by industry representatives 11:00–11:30 am: Questions from the Committee • Introduction Standards for pre-clinical studies Mike Ogden Senior Director of Regulatory Oversight R.J. Reynolds Tobacco Company • Standards for studies on in vitro models of disease Chris Proctor Chief Scientific Officer British American Tobacco • Standards for clinical studies and biomarkers Mohamadi Sarkar Senior Principal Research Scientist Altria Client Services • Population communication and risk perception Lars Erik Rutqvist Senior Vice President for Scientific Affairs Swedish Match • Summary J. Daniel Heck Principal Scientist Lorillard Tobacco Company
OCR for page 349
349 APPENDIX D 11:30 am– Andrew Salmon 12:00 pm Senior Toxicologist and Chief Air Toxicology and Risk Assessment Section Office of Environmental Health Hazard Assessment California Environmental Protection Agency 12:00–1:00 pm Lunch 1:00–1:30 pm David Jacobson-Kram Associate Director of Pharmacology and Toxicology Office of New Drugs Food and Drug Administration 1:30–2:00 pm Peter G. Shields Professor of Medicine and Oncology Deputy Director, Lombardi Comprehensive Cancer Center Georgetown University Mirjana Djordjevic Health Scientist Administrator Tobacco Control Research Branch National Cancer Institute 2:00–2:30 pm John Baron Professor of Medicine Dartmouth Medical School 2:30–2:45 pm Break 2:45–3:15 pm Brenda Edwards Associate Director Surveillance Research Program National Cancer Institute 3:15–3:45 pm Ruth S. Day Director Medical Cognition Laboratory Duke University 3:45–4:15 pm David Mendez Associate Professor Department of Health Management and Policy University of Michigan School of Public Health
OCR for page 350
350 STUDIES ON MODIFIED RISK TOBACCO PRODUCTS 4:15–4:30 pm Break 4:30–6:00 pm Panel Discussion II: public health representatives Moderator: Dan Carpenter 4:30–5:30 pm: Presentations by public health representatives 5:30–6:00 pm: Questions from the Committee • David Abrams Executive Director The Schroeder Institute for Tobacco Research and Policy Studies Professor, Department of Health, Behavior and Society The Johns Hopkins Bloomberg School of Public Health • Tom Glynn Director, Cancer Science and Trends Director, International Cancer Control American Cancer Society • Mark Greenwold Director, Regulatory Affairs Campaign for Tobacco-Free Kids • Rose Marie Robertson Chief Science Officer American Heart Association • Mitch Zeller Vice President for Policy and Strategic Communications Pinney Associates 6:00 pm Adjourn